Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy

TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2

(2018) Zhanyao Tan et al.   ONCOGENE

PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models

(2016) Fan Lin et al.   CLINICAL CANCER RESEARCH

Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells

(2015) DONG SHEN et al.   ONCOLOGY REPORTS

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma

(2015) Sara Pessina et al.   OncoImmunology

TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway

(2014) L-H Zhang et al.   ONCOGENE

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/ -catenin pathway

(2013) C. Riganti et al.   NEURO-ONCOLOGY

An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma

(2013) Esther Rheinbay et al.   Cell Reports

GSK3b-inhibitor lithium chloride enhances activation of Wnt canonical signaling and osteoblast differentiation on hydrophilic titanium surfaces

(2012) C. Galli et al.   CLINICAL ORAL IMPLANTS RESEARCH

Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells

(2012) Martin Bezler et al.   Molecular Oncology

Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability

(2012) Naihan Xu et al.   Journal of Oncology

Unknown

(2011) Ilya Ulasov et al.   MOLECULAR MEDICINE

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY